There is an urgent need for cost-effective, noninvasive diagnostic techniques for the evaluation of breast lesions.While contrast-enhanced magnetic resonance imaging (MRI) now provide very high sensitivity for the detection of breast lesions, specificity remains relatively low, resulting in many unnecessary biopsies of benign lesions.Magnetic Resonance Spectroscopy (1H MRS) used in conjunction with MRI provides useful information about the pathology of breast lesions by the measurement of diagnostic chemicals visible on the MR timescale.Spectroscopic measurements can be obtained following contrast-enhanced MR imaging by applying a point-resolved spatially localized spectroscopy sequence.The observation of resonances at discrete spectral frequencies allows an accurate diagnosis.In.spectra obtained in malignant breast cancers, an observed resonance at 3.23 ppm is consistent with phosphocholine.